Trials / Recruiting
RecruitingNCT07107126
Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemia Activity of RPT1G in Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Remedy Plan, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main goals of this study are to learn if RPT1G is safe and tolerable and to determine the best dose and schedule of RPT1G for patients with relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RPT1G | RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally. |
Timeline
- Start date
- 2026-02-13
- Primary completion
- 2028-12-01
- Completion
- 2028-12-01
- First posted
- 2025-08-06
- Last updated
- 2026-03-25
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07107126. Inclusion in this directory is not an endorsement.